Drug Profile
Research programme: respiratory disorder therapies - Enterprise Therapeutics
Latest Information Update: 21 Jun 2021
Price :
$50
*
At a glance
- Originator Enterprise Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Respiration disorders
Most Recent Events
- 21 Jun 2021 Early research in Respiration disorders in United Kingdom (unspecified route) (Enterprise Therapeutics pipeline, June 2021)